• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Azenta Inc.

    11/13/24 4:05:02 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology
    Get the next $AZTA alert in real time by email
    SC 13G/A 1 fp0090889-3_sc13ga.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (AMENDMENT NO. 3)*

     

    AZENTA, INC.

     

    (Name of Issuer)

     

    Common Stock

     

    (Title of Class of Securities)

     

    114340102

     

    (CUSIP Number)

     

    September 30, 2024

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X] Rule 13d-1(b) 

    [  ] Rule 13d-1(c) 

    [  ] Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 114340102   13G   Page 2 of 5 Pages

     

    1.

    NAMES OF REPORTING PERSONS OR 

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Kayne Anderson Rudnick Investment Management, LLC 

    95-4575414

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 

    (see instructions)

    (a) [   ]

    (b) [   ]

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION 

     

    A California Limited Liability Company

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER 

    1,316,860

    6.

    SHARED VOTING POWER

    565,436

    7.

    SOLE DISPOSITIVE POWER

    1,714,558

    8.

    SHARED DISPOSITIVE POWER

    565,436

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 

    2,279,994

     
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 

    (see instructions) [   ] 

     

     
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 

    4.66%

     
    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IA

     

     

     

    CUSIP No. 114340102   13G   Page 3 of 5 Pages

     

    Item 1. (a)

    Name of Issuer

    Azenta, Inc.

         
      (b)

    Address of Issuer’s Principal Executive Offices

    200 Summit Drive, Burlington, MA 01803

     

    Item 2. (a)

    Name of Person Filing

    Kayne Anderson Rudnick Investment Management, LLC

         
      (b)

    Address of the Principal Office or, if none, residence

    2000 Avenue of the Stars, Suite 1110, Los Angeles, CA 90067

         
      (c)

    Citizenship

    A California Limited Liability Company

         
      (d)

    Title of Class of Securities

    Common Stock

         
      (e)

    CUSIP Number

    114340102

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) [  ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) [  ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) [  ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) [  ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [X] An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) [  ] An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) [  ] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) [  ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) [  ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) [  ] Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

    CUSIP No. 114340102   13G   Page 4 of 5 Pages

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a) Amount beneficially owned: 2,279,994
    (b) Percent of class: 4.66%
    (c) Number of shares as to which the person has:
      (i) Sole power to vote or to direct the vote: 1,316,860
      (ii) Shared power to vote or to direct the vote: 565,436
      (iii) Sole power to dispose or to direct the disposition of: 1,714,558
      (iv) Shared power to dispose or to direct the disposition of: 565,436

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ]. 

    Instruction. Dissolution of a group requires a response to this item.

     

    The reporting person has ceased to be the beneficial owner of more than five percent of the class of securities.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    N/A

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    N/A

     

    Item 8. Identification and Classification of Members of the Group.

     

    N/A

     

    Item 9. Notice of Dissolution of Group.

     

    N/A

     

     

    CUSIP No. 114340102   13G   Page 5 of 5 Pages

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Kayne Anderson Rudnick Investment Management, LLC
           
      By: /s/ Michael Shoemaker  
      Name: Michael Shoemaker
      Title: Chief Compliance Officer
      Date: November 13, 2024
    Get the next $AZTA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZTA

    DatePrice TargetRatingAnalyst
    8/6/2025$35.00Mkt Perform → Outperform
    Raymond James
    7/22/2025$35.00Equal-Weight
    Stephens
    12/18/2024$50.00 → $60.00Equal-Weight → Overweight
    Stephens
    4/4/2024$64.00Hold
    Jefferies
    2/1/2024$61.00 → $79.00Buy
    B. Riley Securities
    7/19/2023Mkt Perform
    Raymond James
    5/10/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    2/9/2023$65.00 → $60.00Overweight → Equal-Weight
    Stephens
    More analyst ratings

    $AZTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Azenta upgraded by Raymond James with a new price target

    Raymond James upgraded Azenta from Mkt Perform to Outperform and set a new price target of $35.00

    8/6/25 7:48:53 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Stephens resumed coverage on Azenta with a new price target

    Stephens resumed coverage of Azenta with a rating of Equal-Weight and set a new price target of $35.00

    7/22/25 7:51:21 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta upgraded by Stephens with a new price target

    Stephens upgraded Azenta from Equal-Weight to Overweight and set a new price target of $60.00 from $50.00 previously

    12/18/24 7:25:24 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025; Reiterates Full Year Fiscal 2025 Guidance

    BURLINGTON, Mass., Aug. 5, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2025 2025 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 144 $ 143 $ 144 0 % (0) % Organic growth (2) % Sample Management Solutions $ 78 $ 80 $ 81 (3) % (4) % Multiomics $ 66 $ 64 $ 64 4 % 4 % Diluted EPS Continuing Operations

    8/5/25 6:30:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Life Sciences Partners with Frenova, a Division of Fresenius Medical Care, and Nephronomics to Advance Genomic Research in Nephrology

    BURLINGTON, Mass., July 31, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has entered a collaboration with Frenova, a division of Fresenius Medical Care, and Nephronomics, a Renal Precision Medicine company, to begin genomic sequencing and data generation for Frenova's transformative MyReason® genomics research program. This strategic collaboration aims to leverage cutting-edge technologies to enhance the understanding of cardio-kidney-metabolic diseases and drive advancements in precision medicine for patients worldwide. The MyReason research program is an innovative initiative designed to uncover insights into the genetic mechanisms underlying kidney disease. To d

    7/31/25 4:05:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Fresenius Medical Care's Third-Party Clinical Research Organization Frenova Announces Strategic Collaboration Advancing Genomics-Driven, Precision Kidney Disease Care

    Frenova and Nephronomics, a renal precision company co-founded by Fresenius Medical Care, initiate collaboration with GENEWIZ by Azenta Life SciencesProvides vital insights through sophisticated genomic sequencing and analysis of Frenova's My Reason® genomic and clinical data registryPaves way for advances in precision kidney disease care, novel therapies, and diagnosticsBAD HOMBURG, Germany, July 31, 2025 /PRNewswire/ -- Fresenius Medical Care today announced that Frenova, the company's third-party clinical research organization, along with Nephronomics, a renal precision medicine company, and GENEWIZ by Azenta Life Sciences, have entered a collaboration to advance the genomic analysis effo

    7/31/25 8:30:00 AM ET
    $AZTA
    $FMS
    Industrial Machinery/Components
    Technology
    Misc Health and Biotechnology Services
    Health Care

    $AZTA
    SEC Filings

    View All

    SEC Form 10-Q filed by Azenta Inc.

    10-Q - Azenta, Inc. (0000933974) (Filer)

    8/6/25 5:19:09 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Azenta, Inc. (0000933974) (Filer)

    8/5/25 6:50:45 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Inc. filed SEC Form 8-K: Leadership Update

    8-K - Azenta, Inc. (0000933974) (Filer)

    7/2/25 4:15:22 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP and GM, Multiomics Zhou Ginger returned $30,966 worth of Common to the company (1,085 units at $28.54), decreasing direct ownership by 4% to 26,831 units (SEC Form 4)

    4 - Azenta, Inc. (0000933974) (Issuer)

    8/13/25 4:47:44 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    SVP and CHRO Pirogova Olga returned $30,966 worth of Common to the company (1,085 units at $28.54), decreasing direct ownership by 6% to 18,288 units (SEC Form 4)

    4 - Azenta, Inc. (0000933974) (Issuer)

    8/13/25 4:44:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    EVP, CFO and Treasurer Lin Lawrence Y. bought $69,900 worth of Common (2,500 units at $27.96), increasing direct ownership by 6% to 46,013 units (SEC Form 4)

    4 - Azenta, Inc. (0000933974) (Issuer)

    8/12/25 4:05:13 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CFO and Treasurer Lin Lawrence Y. bought $69,900 worth of Common (2,500 units at $27.96), increasing direct ownership by 6% to 46,013 units (SEC Form 4)

    4 - Azenta, Inc. (0000933974) (Issuer)

    8/12/25 4:05:13 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    SVP and General Manager, Genom Zhou Ginger bought $19,132 worth of Common (417 units at $45.88), increasing direct ownership by 2% to 27,916 units (SEC Form 4)

    4 - Azenta, Inc. (0000933974) (Issuer)

    2/4/25 4:10:05 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    President and CEO Marotta John was granted 83,622 units of Common and bought $552,904 worth of Common (13,967 units at $39.59), increasing direct ownership by 2,982% to 100,862 units (SEC Form 4)

    4 - Azenta, Inc. (0000933974) (Issuer)

    11/19/24 4:10:16 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Leadership Updates

    Live Leadership Updates

    View All

    Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600

    NEW YORK, Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE:ENV) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 25. Bain Capital is acquiring Envestnet in a deal expected to be completed soon, pending final closing conditions. Azenta's market capitalization is no longer representative of the mid-cap market space.Concentra Group Holdings Inc. (NYSE:CON) will replace Myers Industries Inc. (NYSE:MYE) in the S&P SmallCap 600 effective prior to the openin

    11/19/24 5:56:00 PM ET
    $AZTA
    $CON
    $ENV
    Industrial Machinery/Components
    Technology
    Medical Specialities
    Health Care

    Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value

    William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced the appointment of three new independent directors to its Board. William Cornog, former head of KKR Capstone, the portfolio operations team of KKR & Co., and Alan Malus, former Corporate Executive Vice President of Thermo Fisher, join as part of Azenta's ongoing i

    11/4/24 8:00:00 AM ET
    $AZTA
    $BV
    $LVWR
    Industrial Machinery/Components
    Technology
    Real Estate
    Motor Vehicles

    AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO

    Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition.  Mr. Marotta has two decades of experience leading global companies in life sciences, medical devices, and diagnostics, and is joining Azenta from Patient Square Capital, a leading healthcare investment firm, where he serves as Executive in Residence. P

    9/4/24 8:00:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Azenta Inc.

    SC 13G/A - Azenta, Inc. (0000933974) (Subject)

    11/13/24 4:05:02 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Amendment: SEC Form SC 13D/A filed by Azenta Inc.

    SC 13D/A - Azenta, Inc. (0000933974) (Subject)

    11/4/24 8:41:47 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    SEC Form SC 13G filed by Azenta Inc.

    SC 13G - Azenta, Inc. (0000933974) (Subject)

    10/31/24 11:55:02 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Financials

    Live finance-specific insights

    View All

    Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025; Reiterates Full Year Fiscal 2025 Guidance

    BURLINGTON, Mass., Aug. 5, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2025 2025 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 144 $ 143 $ 144 0 % (0) % Organic growth (2) % Sample Management Solutions $ 78 $ 80 $ 81 (3) % (4) % Multiomics $ 66 $ 64 $ 64 4 % 4 % Diluted EPS Continuing Operations

    8/5/25 6:30:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Announces Fiscal 2025 Third Quarter Earnings Conference Call and Webcast

    BURLINGTON, Mass., July 23, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal third quarter 2025 earnings which ended on June 30, 2025, on Tuesday August 5, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, August 5, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on August 6, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling imp

    7/23/25 4:05:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025

    BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2025 2024 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 143 $ 148 $ 136 (3) % 5 % Organic growth 6 % Sample Management Solutions $ 80 $ 81 $ 74 (2) % 8 % Multiomics $ 64 $ 66 $ 62 (4) % 2 % Diluted EPS Continuing Operat

    5/7/25 6:30:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology